Additionally, an immunosuppressive TME—characterized by the accumulation of regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages—leverages the PD-1/PD-L1 axis to dampen antitumor immunity, facilitating disease progression and therapeutic resistance [37]. This evidence concerns the gene PDCD1 and neoplasm.